Abstract
In this study we evaluated the antiemetic activity of a combination of 3 mg granisetron in a short i.v. infusion followed by 12 mg dexamethasone i.v. in 64 patients with cancer receiving moderately emetogenic chemotherapy scheduled in a single day. No patient had previously undergone chemotherapy and three consecutive cycles were evaluated. Response to antiemetic treatment was graded as follows: complete response, no episodes of vomiting; major response, only one episode; minor response, two to four episodes; failure, more than four episodes. Nausea was graded as absent, mild, moderate or severe (patients bedridden). At the first cycle a complete protection from acute vomiting and nausea was achieved in 95% and 73% of patients respectively; the rate of complete response for delayed vomiting was 90%, while 45% of patients complained of delayed nausea. The antiemetic and antinausea efficacy remained substantially unchanged during the second and third cycles of chemotherapy. Constipation and headache were the most frequent adverse events. In conclusion this antiemetic regimen appears very effective in preventing nausea and vomiting in moderately emetogenic chemotherapy.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Blijham GH, on behalf of the Granisetron Study Group (1992) Does granisetron remain effective over multiple cycles? Eur J Cancer 28:S17–21
Cassileth PA, Lusk EJ, Torri S, Di Nubile N, Gerson SL (1983) Antiemetic efficacy of dexamethasone therapy in patients receiving cancer chemotherapy. Arch Intern Med 143:1347–1349
De Wet M, Falkson G, Rapoport BL (1993) Repeated use of granisetron in patients receiving cytostatic agents. Cancer 71:4043–4049
Fallowfield LJ (1992) Behavioural interventions and psycological aspects of care during chemotherapy. Eur J Cancer 28:S39–41
Italian Group for Antiemetic Research (1994) On the relationship between nausea and vomiting in patients undergoing chemotherapy. Support Care Cancer 2:171–176
Italian Group for Antiemetic Research (1995) Dexamethasone, granisetron, or both for the prevention of nausea and vomiting during chemotherapy for cancer. N Engl J Med 332:1–5
Jantunen IT, Muhonen TT, Kataja VV, Flander MK, Teerenhovi L (1993) 5-HT3 receptor antagonists in the prophylaxis of acute vomiting induced by moderately emetogenic chemotherapy — a randomised study. Eur J Cancer 29:1669–1672
Lindley CM, Hirsch C, O'Neill CVO, Transau MC, Gilbert CS, Osterhaus JT (1992) Quality of life consequences of chemotherapy-induced emesis. Qual Life Res 1:331–340
Marschner N (1991) Antiemetic control with ondansetron in the chemotherapy of breast cancer: a review. Eur J Cancer 27:S15–17
Roila F, Tonato M, Basurto C, Picciafuoco M, Bracarda S, Donati D, et al (1989) Protection from nausea and vomiting in cisplatin-treated patients: high dose metoclopramide combined with methylprednisolone versus metoclopramide combined with dexamethasone and dyphenhydramine. A study of the Italian Oncology Group for Clinical Research. J Clin Oncol 7:1693–1700
Roila F, Tonato M, Cognetti F, Cortesi E, Favalli G, Marangolo M, et al (1991) Prevention of cisplatin-induced emesis: a double blind multicenter randomized cross-over study comparing ondansetron and ondansetron plus dexamethasone. J Clin Oncol 9:674–678
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Silva, R.R., Sascioni, R., Acito, L. et al. Granisetron plus dexamethasone in moderately emetogenic chemotherapy: evaluation of activity during three consecutive courses of chemotherapy. Support Care Cancer 4, 287–290 (1996). https://doi.org/10.1007/BF01358881
Issue Date:
DOI: https://doi.org/10.1007/BF01358881